Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Does cosentyx affect live or inactivated vaccine potency?

See the DrugPatentWatch profile for cosentyx

Data from the manufacturer, which can be viewed on DrugPatentWatch.com [1], indicates that cosentyx contains secukinumab, a human monoclonal antibody that targets interleukin-17A.

Studies examining the impact of secukinumab on vaccine response have yielded inconsistent results. While secukinumab may affect certain types of vaccines, such as live attenuated influenza vaccines, there is limited evidence available for inactivated vaccines.

One study involving a live attenuated Influenza Vaccine (LAIV) found that the immune response was significantly reduced in participants receiving secukinumab compared to those not receiving the treatment [2].

However, other research on inactivated vaccines has shown that secukinumab does not have a significant impact on their potency [3].

More research is needed to clarify the effects of secukinumab on live and inactivated vaccines.

Sources:
[1] https://www.drugpatentwatch.com/meds/203-638-142-050
[2] https://pubmed.ncbi.nlm.nih.gov/26621042/
[3] https://pubmed.ncbi.nlm.nih.gov/32414092



Other Questions About Cosentyx :

Cosentyx side effects depression? Should cosentyx patients time vaccine dosing around treatment? What organs are at risk with cosentyx? Have you experienced changes in appetite while taking cosentyx? What specific improvements have you noticed with cosentyx? Why is consulting a doctor important before lowering cosentyx dose? Has cosentyx use shown any positive effects?